Description: Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Home Page: talphera.com
1850 Gateway Drive
San Mateo,
CA
94404
United States
Phone:
650 216 3500
Officers
| Name | Title |
|---|---|
| Mr. Vincent J. Angotti | CEO & Director |
| Mr. Raffi Mark Asadorian | Chief Financial Officer |
| Mr. Anil N. Dasu | Chief Engineering Officer |
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2014 |
| Price-to-Sales TTM: | 38.4264 |
| IPO Date: | 2011-02-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |